Biomarin Pharmaceutical Inc.’s data supporting the use of Voxzogo (vosoritide) in children with the most common form of dwarfism proved compelling for the FDA, which cleared the modified C-type natriuretic peptide as the first treatment for the rare genetic disease affecting bone growth. Read More
Sotio Biotech AS has licensed Legochem Biosciences Inc.’s technology for five new antibody-drug conjugates (ADC) in a deal that could bring the latter over $1 billion. Read More
The FDA amended emergency use authorizations (EUAs) for the Moderna Inc. COVID-19 vaccine as well as the shot from Pfizer Inc. and Biontech SE. A single booster dose was green-lighted for people 18 years and older at least six months after finishing the primary regimen with either of the vaccines, or at least two months after getting the Johnson & Johnson shot. Read More
Efforts to find new treatments for cancer and infectious diseases account for nearly half of the phase I, II and III clinical data recorded in 2021. Read More
A phase IIb trial of Connect Biopharma Holdings Ltd.'s CBP-201 in adults with moderate-to-severe atopic dermatitis (AD) showed all three doses tested reduced eczema severity vs. placebo by a statistically significant percentage at 16 weeks, meeting the trial's primary efficacy endpoint. Read More
New conditioning agents for hematopoietic stem cell transplant (HSCT) are in the works at a handful of companies, with Jasper Therapeutics Inc. ushering through the pipeline a candidate viewed by some on Wall Street as especially promising. Read More
LONDON – Medical research charities that form an integral part of the U.K. health research system are still reeling from the impact of COVID-19 and now expect it will be three years before funding returns to pre-pandemic levels. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: AL-S, Astrazeneca, Cassava Sciences, Daiichi Sankyo, Gannex, Imstem, Innovation, Kintara, Moderna, Ox2, Polypid, Tempest. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Armata, Bridgebio, Cellectis, Curevac, Cytodyn, Cytovia, Enterin, Glaxosmithkline, Helsinn, Innovation, Locanabio, Pfizer, Schrödinger, Second Genome, Shenzhen Kangtai Biological Products, Voyager. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Armata, Heron, Longeveron, Mediwound, Merck, Molecular Templates, Verrica, Vitro. Read More
